Imara to Webcast Conference Call of Second Quarter 2020 Financial Results
Imara Inc. (Nasdaq: IMRA) will host a conference call and live webcast on August 14, 2020, at 8:30 a.m. ET to discuss Q2 2020 financial results and business updates. This clinical-stage biopharmaceutical company focuses on developing therapeutics for rare genetic disorders of hemoglobin. Its lead candidate, IMR-687, is a small molecule inhibitor designed for sickle cell disease and beta-thalassemia treatment. Investors can access the webcast on the Imara website, and further details are available through investor relations contacts.
- Scheduled discussion of Q2 2020 financial results, potentially indicating transparency and shareholder engagement.
- Focus on developing IMR-687, a promising treatment for sickle cell disease and beta-thalassemia.
- None.
BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, August 14, 2020, at 8:30 a.m. ET to discuss its second quarter 2020 financial results and other business updates.
A live webcast will be available under "Events and Presentations" in the Investors section of the company's website at imaratx.com. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 9775635. A replay of the webcast will be archived on the Imara website following the presentation.
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.
Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com
FAQ
When will Imara announce its Q2 2020 financial results?
What is IMR-687?
How can I access Imara's conference call?
